Analytical outlook for biosimilar development


Thursday, April 29, 2021


03:00 PM Europe/Warsaw

Convert to my timezone
This field is required.
This field is required.
This field is required.
This field is required.
This field is required.
Required fields
If you have already registered and can't locate your registration confirmation email, click here!
The email address is incorrect. Please double-check your email address.

A confirmation email with logging details has been sent to the provided email.

System configuration test. Click here!


The variability and complexity of biological medicines compel extensive and comprehensive characterization studies to ensure safety and efficacy. Compared to small-molecule drugs, structural and functional characterization of biologics can be a tedious and challenging process. It involves using state-of-the-art technologies to evaluate the purity, specificity, potency, and toxicity, all in accordance with international regulatory guidelines. During the webinar, Selvita’s Experts intend to characterize regulatory requirements and provide an outlook for analytical approaches for biosimilar development and manufacturing process changes.

The webinar will feature a discussion between some of Selvita’s most experienced scientific team members: Magdalena Bielak-Łakomska, Associate Director in Analytics, and Jan Smagur, Director of Cell and Molecular Biology Laboratory, moderated by Krzysztof Stawujak, Business Development Manager.


  1. 15:00 to 15:05: Introduction – Krzysztof Stawujak
  2. 15:05 to 15:35: Presentation: Analytical outlook for biosimilar development – Magdalena Bielak-Łakomska, Jan Smagur
  3. 15:35 to 16:00: Q&A session

Krzysztof Stawujak

Business Development Manager, Selvita S.A.

Magdalena Bielak-Łakomska

Associate Director in Analytics, Selvita S.A.

Jan Smagur

Director of Cell and Molecular Biology Laboratory, Selvita S.A.